RxSight, Inc. Financing Receivable, Allowance for Credit Loss
RxSight, Inc. (RXST) had Financing Receivable, Allowance for Credit Loss of $0 as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Balance Sheet › Assets
us-gaap:FinancingReceivableAllowanceForCreditLosses · last filed 2026-02-25
- 2025-12-31: Financing Receivable, Allowance for Credit Loss $0.00.
- 2024-12-31: Financing Receivable, Allowance for Credit Loss $0.00.
- 2023-12-31: Financing Receivable, Allowance for Credit Loss $0.00.
- 2022-12-31: Financing Receivable, Allowance for Credit Loss $0.00.
| Period end | Financing Receivable, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |